Baxter International (NYSE:BAX) has agreed to acquire privately held Cheetah Medical, a provider of non-invasive hemodynamic monitoring technologies, for up to $230M in cash, consisting of $190M upfront and $40M contingent on the achievement of certain clinical and commercial milestones.
The transaction should close next quarter. Baxter does not expect it to have a material impact on 2019 or 2020 earnings.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.